Drug Profile
Research programme: coronavirus inhibitors - EpiCept Corporation
Alternative Names: MX-128533Latest Information Update: 07 Feb 2011
Price :
$50
*
At a glance
- Originator EpiCept Corporation
- Developer EpiCept Corporation; National Institute of Allergy and Infectious Diseases
- Class Ketones; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Severe acute respiratory syndrome
Most Recent Events
- 09 Jan 2006 Maxim Pharmaceuticals has been acquired and merged into EpiCept Corporation
- 01 Mar 2004 Coronavirus inhibitors are available for licensing worldwide (http://www.maxim.com)
- 30 Jan 2004 Preclinical trials in Severe acute respiratory syndrome in USA (unspecified route)